Cyclosporine has revolutionised the transplantation scene in the last 20 years by helping with immunosuppresion. Novartis have so far had the patent
Cyclosporine has revolutionised the transplantation scene in the last 20 years by helping with immunosuppresion. Novartis have so far had the patent for the drug and enjoyed the profits. The cost of the medicine is prohibitively expensive.However in the past few years other pharma companies have been allowed to manufacture the drug giving Novartis a competetion. The current tablet size are big and makes it uncomfortable to swallow.
The pharmaceutical company SangStat expects to launch significantly smaller cyclosporine capsule in Europe. The new cyclosporine capsule is significantly smaller than any cyclosporine capsule currently on the market."The replacement of our current capsule filing with this new capsule could offer SangStat a significant advantage over a 'me too' generic cyclosporine capsule in Europe" said Jean-Jacques Bienaimi, President and CEO. "This is a very positive development for SangStat. Compared to our current capsule product, we believe it has a stronger patent position and improved product characteristics."
SangStat competetors Novartis have a lawsuit filed against the company for SangCya oral solution.
